Canada· CA-DIN-02342227
CERVARIX
A humaner papillomvirus (typen 16, 18) product containing recombinant human papillomavirus type 16 l1 protein + recombinant human papillomavirus type 18 l1 protein, registered in Canada by GLAXOSMITHKLINE INC. The same ATC class is registered in 10 of our 19 countries.
Checked against Health Canada Drug Product Database (Canada) on
Informational only — not a medical device.
Where it is registered
Humaner papillomvirus (typen 16, 18) is registered in 10 of 19 countries.
Countries holding a registration under ATC J07BM02 (humaner papillomvirus (typen 16, 18)), each read from that country’s own register.
- This record: Canada, from Health Canada Drug Product Database (Canada)
- 6 of them publish a price we can compare per daily dose
Humaner papillomvirus (typen 16, 18) · ATC J07BM02
10 / 19 countries
- Belgiumprice
- Canada
- Czechiaprice
- Denmark
- Finlandprice
- Icelandprice
- Ireland
- Netherlands
- Norwayprice
- Polandprice
The record
At a glance
Health Canada Drug Product Database (Canada)- Active substance
- RECOMBINANT HUMAN PAPILLOMAVIRUS TYPE 16 L1 PROTEIN + RECOMBINANT HUMAN PAPILLOMAVIRUS TYPE 18 L1 PROTEIN
- Manufacturer
- GLAXOSMITHKLINE INC
- Country
- Canada (CA)
- ATC code
- J07BM02
- ATC class
- Humaner Papillomvirus (Typen 16, 18)
- Reimbursed
- Not published by this register
- Source register
- Health Canada Drug Product Database (Canada)
- Last checked
- October 1, 2026
Packs & prices · 0
No packs listed by the register for this record.
Regulatory notes
No shortage, Orange Book or US label notes for this record.
Same medicine, other countries
Humaner papillomvirus (typen 16, 18) in 1 other country
What each register calls a product with the same active substance — salts and hydrates count as the same.
Sourced from a public register and reproduced with attribution. Drug Database is not affiliated with, endorsed by, or a partner of Health Canada Drug Product Database (Canada). This is an informational data service and not a medical device — verify against the official source of record before any clinical decision.
For developers
The same record over the API, and the raw payload
GET /v1/drugs/9cf7041a-6e3a-441e-bcc5-96b6a2ccfd02 GET /v1/drugs/9cf7041a-6e3a-441e-bcc5-96b6a2ccfd02?format=fhir
Every response carries last_synced_at, so freshness is a field rather than a promise. Below is exactly what the ingestion wrote, before any presentation — the same JSON the API returns under payload.
{
"din": "02342227",
"form": "SUSPENSION",
"class": "Human",
"routes": [
"INTRAMUSCULAR"
],
"source": "health_canada_dpd",
"status": "MARKETED",
"atc_raw": "J07BM02",
"schedule": [
"Schedule D"
],
"drug_code": "82773",
"strengths": [
"20 MCG"
],
"ahfs_class": null,
"substances": [
"RECOMBINANT HUMAN PAPILLOMAVIRUS TYPE 16 L1 PROTEIN",
"RECOMBINANT HUMAN PAPILLOMAVIRUS TYPE 18 L1 PROTEIN"
],
"product_categorization": null
}See everything about humaner papillomvirus (typen 16, 18).
This page is the registration. A free account adds the label text as the regulator wrote it, what it costs per daily dose across the markets that publish a price, a feed of what changes in the registers, and an assistant that answers with its sources. Interaction severity is free; mechanism and management are on the Growth plan. No card, nothing to install.